The first domestic new crown and antibody drug!Tsinghua leads research and development

Recently, Professor Zhang Linqi, the research team of Professor Zhang Linqi, Director of the Global Health and Infectious Disease Research Center of Tsinghua University, Tsinghua University Global Health and Infectious Disease Research Center and AIDS Comprehensive Research Center, and Shenzhen Third People's Hospital and Tengshengbo Pharmaceutical Co., Ltd. Anti -antibody Anbawe monoclonal anti -anti -anti -anti -antibody antibody antibody therapy was listed in commercialization in China.

New Crown and Antibody Ambale Mippitive and Romi Siwei's Single Anti -combined therapy

The combination of Antimetabu and Romi Siwei Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -therapy approval was obtained on December 8, 2021. Death) Adults and adolescents (12-17 years old, weight ≥40 kg) new coronary virus infection (COVID-19) patients with high risk factors. Among them, adolescent indications are approved by the attachment. On March 15, 2022, the National Health and Health Commission included the medicine into the "New Coronatte Virus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" for treatment of anti -new coronary virus pneumonia.

Screenshot of the webpage of "New Coronary Virus Pneumonia Diagnosis and Treatment (Trial Ninth Edition)"

On July 11, the new crown and antibodies Ambellipoplasty and Romi Siwei's anti -combined therapy drug transfer ceremony was held in Shenzhen Third People's Hospital.

This is the first batch of drugs supplied to the market after the listing of domestic new crown antibody drugs. A total of 100 people are stored in the environment of 2 degrees Celsius to 8 degrees Celsius.

The first batch of domestic new crown special medicine for commercialization is the first batch of depth of depth

At present, this new drug has been taken the lead in Shenzhen Third People's Hospital. A 82 -year -old new crown Omircong mutant strain has been successfully used in the hospital. Essence

After the medication, the patient's various immune mechanisms have been effectively improved, the amount of virus has decreased sharply, and the effect of medication is obvious.

Lu Hongzhou, Dean of Shenzhen Third Hospital, introduced that the neutral and antibody drugs are relatively widely adapted to patients and are also applicable to mild patients with high virus load.

He said that the next step will continue to accumulate more four -phase clinical experimental data, and use real clinical data to tell you the clinical effects of the drug.

Anbawei's related information about the combination therapy

The first domestic neutralized antibody drugs faced mutant viruses, showing a broad -spectrum. According to Lu Hongzhou, combined with the laboratory's false virus results and dosage doses and pharmacokinetic model data, Anbawei's monoclonal anti -anti -anticipated combination therapy showed a good virus inhibitory effect on the Omikon mutation.

Why can this neo -crown and antibody drugs continue to be effective in the face of the continuous mutation of the new coronal virus?

Zhang Linqi, the head of the R & D team and a professor at the School of Medicine of Tsinghua University, revealed to reporters that everyone uses the "antibody pair" method to avoid virus escape, but the "antibody is right". The two antibodies must cooperate with each other and can play a combination of fists, such as identifying different locations of the virus and different mechanisms to inhibit the virus. Based on the refined research on the interaction of the entire virus and antibodies, the team finally screened the "antibody pair" that can coordinate each other in the 206 candidate antibodies to coordinate each other, and found the "best partner".

Professor Zhang Linqi and his team

The person in charge of the relevant enterprise said that the team's antibody combination therapy for this antibody combination therapy is in progress to the live virus in BA.4/5 and BA.2.12.1.

Source | China News Agency Hong Kong Wenhui.com

Capture | Yang Tianshu

Edit | Yang Tianshu Jiang Shengying

- END -